Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
$82.24
-3.1%
$77.62
$32.89
$88.31
$10.56B0.422.47 million shs1.89 million shs
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
$303.96
+1.8%
$290.06
$249.12
$385.22
$32.77B0.49270,130 shs459,223 shs
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
$183.95
-1.6%
$162.03
$34.00
$193.82
$39.73B1.373.02 million shs1.71 million shs
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
$32.15
-2.4%
$34.08
$14.99
$37.35
$37.89B0.865.26 million shs4.23 million shs
Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
0.00%-1.87%+20.98%+27.20%+129.32%
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
0.00%+0.35%+12.94%-2.27%+19.34%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
0.00%-1.25%+21.45%+37.11%+391.53%
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
0.00%-5.01%-5.07%+5.55%+100.26%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
$82.24
-3.1%
$77.62
$32.89
$88.31
$10.56B0.422.47 million shs1.89 million shs
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
$303.96
+1.8%
$290.06
$249.12
$385.22
$32.77B0.49270,130 shs459,223 shs
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
$183.95
-1.6%
$162.03
$34.00
$193.82
$39.73B1.373.02 million shs1.71 million shs
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
$32.15
-2.4%
$34.08
$14.99
$37.35
$37.89B0.865.26 million shs4.23 million shs
Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
0.00%-1.87%+20.98%+27.20%+129.32%
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
0.00%+0.35%+12.94%-2.27%+19.34%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
0.00%-1.25%+21.45%+37.11%+391.53%
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
0.00%-5.01%-5.07%+5.55%+100.26%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
2.91
Moderate Buy$99.9021.47% Upside
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
2.80
Moderate Buy$391.3828.76% Upside
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
2.95
Moderate Buy$144.00-21.72% Downside
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
2.80
Moderate Buy$41.7829.94% Upside

Current Analyst Ratings Breakdown

Latest CYTK, RVMD, TEVA, and ONC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/9/2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Boost Price TargetBuy$205.00 ➝ $235.00
7/7/2026
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Lower Price TargetOutperform$119.00 ➝ $117.00
7/7/2026
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
Boost Price TargetOutperform$436.00 ➝ $451.00
7/7/2026
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
Boost Price TargetBuy$413.00 ➝ $416.00
7/6/2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Reiterated RatingBuy$195.00
7/6/2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Boost Price TargetOutperform$185.00 ➝ $215.00
7/3/2026
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
DowngradeStrong-BuyHold
7/2/2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Boost Price TargetOutperform$165.00 ➝ $181.00
7/1/2026
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
Reiterated RatingMarket Outperform$396.00
6/30/2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Boost Price TargetBuy$179.00 ➝ $210.00
6/29/2026
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
UpgradeNeutralBuy$69.00 ➝ $115.00
(Data available from 7/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
$88.04M116.23N/AN/A($5.39) per share-15.26
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
$5.34B6.24$3.98 per share76.42$39.77 per share7.64
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
$11.58M3,377.18N/AN/A$8.44 per share21.80
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
$17.26B2.14$3.64 per share8.83$6.88 per share4.67
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
-$784.96M-$6.84N/AN/AN/A-784.02%N/A-52.86%8/6/2026 (Estimated)
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
$286.93M$4.4768.0028.68N/A8.94%12.06%6.69%N/A
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-$1.13B-$7.07N/AN/AN/AN/A-83.22%-59.06%8/5/2026 (Estimated)
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
$1.41B$1.3324.1710.584.029.01%43.53%8.19%7/29/2026 (Estimated)

Latest CYTK, RVMD, TEVA, and ONC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026Q2 2026
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
-$1.64N/AN/AN/A$17.09 millionN/A
8/5/2026Q2 2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-$1.9617N/AN/AN/A$17.78 millionN/A
7/29/2026Q2 2026
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
$0.29N/AN/AN/A$4.04 billionN/A
5/6/2026Q1 2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-$1.83-$2.29-$0.46-$2.29$2.43 millionN/A
5/5/2026Q1 2026
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
-$1.67-$1.67N/A-$1.67$8.52 million$19.36 million
4/29/2026Q1 2026
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
$0.50$0.53+$0.03$0.31$3.79 billion$3.98 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
N/AN/AN/AN/AN/A
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
N/AN/AN/AN/AN/A
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
N/AN/AN/AN/AN/A
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
N/A
4.21
4.21
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
0.20
3.64
3.27
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
0.19
6.80
6.80
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
1.70
1.01
0.78

Institutional Ownership

CompanyInstitutional Ownership
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
N/A
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
48.55%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
94.34%
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
54.05%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
250124.43 million121.20 millionOptionable
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
12,000109.72 million102.93 millionN/A
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
250212.60 million196.44 millionOptionable
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
33,9501.15 billion1.14 billionOptionable

Recent News About These Companies

Is JNJ Stock a Buy, Sell or Hold Ahead of Q2 Earnings Release?
Teva and Polpharma Biologics sign global deal for ocrelizumab biosimilar

New MarketBeat Followers Over Time

Media Sentiment Over Time

Cytokinetics stock logo

Cytokinetics NASDAQ:CYTK

$82.24 -2.63 (-3.10%)
Closing price 04:00 PM Eastern
Extended Trading
$81.47 -0.77 (-0.93%)
As of 07:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

BeOne Medicines stock logo

BeOne Medicines NASDAQ:ONC

$303.96 +5.26 (+1.76%)
Closing price 04:00 PM Eastern
Extended Trading
$303.88 -0.08 (-0.03%)
As of 05:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Revolution Medicines stock logo

Revolution Medicines NASDAQ:RVMD

$183.95 -2.93 (-1.57%)
Closing price 04:00 PM Eastern
Extended Trading
$182.49 -1.46 (-0.79%)
As of 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Teva Pharmaceutical Industries stock logo

Teva Pharmaceutical Industries NYSE:TEVA

$32.15 -0.80 (-2.42%)
Closing price 03:59 PM Eastern
Extended Trading
$32.27 +0.12 (+0.37%)
As of 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.